echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > CheckMate-816 Phase III data released: neoadjuvant therapy for patients with non-small cell lung cancer, nivolumab combined with chemotherapy can significantly improve event-free survival

    CheckMate-816 Phase III data released: neoadjuvant therapy for patients with non-small cell lung cancer, nivolumab combined with chemotherapy can significantly improve event-free survival

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Lung cancer is the leading cause of cancer deaths worldwide
    .


    Non-small cell lung cancer and small cell lung cancer are the two main types of lung cancer.


    Lung cancer is the leading cause of cancer deaths worldwide


    2021 Nian 11 Yue 8 days, Bristol-Myers Squibb (NYSE: BMY ) announced that, BMY III clinical study of CheckMate-816 study in the IB period to IIIA of resectable non-small cell lung cancer ( NSCLC patients) achieved in improving The primary research endpoint of event-free survival ( EFS )


    Nivolumab is a PD-1 immune checkpoint inhibitor that uniquely uses the body's own immune system to help the body restore its anti- tumor immune response


    Dr.


    CheckMate-816 is a randomized, open-label, multi-center phase III clinical study, which aims to evaluate the efficacy of nivolumab combined with chemotherapy for neoadjuvant treatment of patients with resectable non-small cell lung cancer compared with chemotherapy alone.


    "CheckMate-816 is the first neoadjuvant phase III clinical study of lung cancer immunity , confirming that neoadjuvant immune combination therapy can bring statistically significant and clinically significant benefits to patients with non-metastatic non-small cell lung cancer .
    Previously, Navoli Uumab combined with chemotherapy has been proven to bring statistically significant improvement in the complete remission of tumor pathology without affecting the results of surgery.
    The latest research results now show that it also prolongs the disease-free survival of patients and delays the disease.
    Recurrence or death .


    CheckMate-816 study were previously have been in the 2021 American Association for Cancer Research Annual Meeting ( pCR data) and 2021 announced the American Society of Clinical Oncology Annual Meeting (ending surgery)


    2014 Nian 7 months, Wu Li You is satisfied that the world's first monoclonal antibody to obtain regulatory approval of PD-1 immune checkpoint inhibitor, is currently satisfied Wu Li You monoclonal antibody has more than 65 approved regions, including the United States, European Union, Japan and China
    .
    2015 Nian 10 months, Wu Li You monoclonal antibody and is satisfied that Iraq horses adalimumab injection for the first time to obtain regulatory approval for the treatment of metastatic melanoma, the combination therapy currently has more than 50 approved countries or regions, including the United States, The European Union and China
    .
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.